Advertisement
CBIO vs UTHR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CBIO is a Hold and UTHR is a Hold.
CBIO in downward trend: price dove below 50-day moving average on September 17, 2026
CBIO moved below its 50-day moving average on September 17, 2026 date and that indicates a change from an upward trend to a downward trend. In 36 of 39 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CBIO as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for CBIO turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 32 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 10-day moving average for CBIO crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CBIO entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CBIO's RSI Oscillator exited the oversold zone, 31 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 63 cases where CBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
Following a +10.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBIO advanced for three days, in 197 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
CBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.389) is normal, around the industry mean (26.782). P/E Ratio (1.663) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (35.461) is also within normal values, averaging (437.542).
The Tickeron Profit vs. Risk Rating rating for this company is 55 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. CBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
UTHR in upward trend: 10-day moving average broke above 50-day moving average on October 06, 2026
The 10-day moving average for UTHR crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 30, 2026. You may want to consider a long position or call options on UTHR as a result. In 58 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for UTHR just turned positive on September 30, 2026. Looking at past instances where UTHR's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.
UTHR moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTHR advanced for three days, in 221 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The 10-day RSI Indicator for UTHR moved out of overbought territory on October 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 20 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 51%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 65 cases where UTHR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 66%.
The 50-day moving average for UTHR moved below the 200-day moving average on September 10, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
UTHR broke above its upper Bollinger Band on September 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for UTHR entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. UTHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.254) is normal, around the industry mean (43.873). P/E Ratio (17.397) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (2.205) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (7.418) is also within normal values, averaging (178.797).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
CBIO | UTHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 84 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 45 Fair valued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 55 | 14 | |
SMR RATING 1..100 | 99 | 48 | |
PRICE GROWTH RATING 1..100 | 63 | 43 | |
P/E GROWTH RATING 1..100 | 28 | 32 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CBIO's Valuation (45) in the Biotechnology industry is in the same range as UTHR (76) in the Pharmaceuticals Other industry. This means that CBIO’s stock grew similarly to UTHR’s over the last 12 months.
UTHR's Profit vs Risk Rating (14) in the Pharmaceuticals Other industry is somewhat better than the same rating for CBIO (55) in the Biotechnology industry. This means that UTHR’s stock grew somewhat faster than CBIO’s over the last 12 months.
UTHR's SMR Rating (48) in the Pharmaceuticals Other industry is somewhat better than the same rating for CBIO (99) in the Biotechnology industry. This means that UTHR’s stock grew somewhat faster than CBIO’s over the last 12 months.
UTHR's Price Growth Rating (43) in the Pharmaceuticals Other industry is in the same range as CBIO (63) in the Biotechnology industry. This means that UTHR’s stock grew similarly to CBIO’s over the last 12 months.
CBIO's P/E Growth Rating (28) in the Biotechnology industry is in the same range as UTHR (32) in the Pharmaceuticals Other industry. This means that CBIO’s stock grew similarly to UTHR’s over the last 12 months.
| CBIO | UTHR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 84% | 2 days ago 51% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 66% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 62% |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 67% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 69% |
| Advances ODDS (%) | 6 days ago 84% | 3 days ago 70% |
| Declines ODDS (%) | 2 days ago 88% | 10 days ago 59% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 66% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CBIO’s FA Score shows that 1 FA rating(s) are green while UTHR’s FA Score has 2 green FA rating(s).
- CBIO’s FA Score: 1 green, 4 red.
- UTHR’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CBIO’s TA Score shows that 4 TA indicator(s) are bullish while UTHR’s TA Score has 5 bullish TA indicator(s).
- CBIO’s TA Score: 4 bullish, 6 bearish.
- UTHR’s TA Score: 5 bullish, 6 bearish.
Price Growth
CBIO (@Biotechnology) experienced а -4.86% price change this week, while UTHR (@Pharmaceuticals: Generic) price change was +0.33% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.22%. For the same industry, the average monthly price growth was -17.98%, and the average quarterly price growth was -18.86%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -5.16%. For the same industry, the average monthly price growth was -5.18%, and the average quarterly price growth was +11.32%.
Reported Earning Dates
CBIO is expected to report earnings on Nov 05, 2026.
UTHR is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-7.22% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (-5.16% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
CBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, CBIO has been loosely correlated with SMMT. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CBIO jumps, then SMMT could also see price increases.
| Ticker / NAME | Correlation To CBIO | 1D Price Change % | ||
|---|---|---|---|---|
| CBIO | 100% | -10.72% | ||
| SMMT - CBIO | 37% Loosely correlated | -9.40% | ||
| UTHR - CBIO | 36% Loosely correlated | -1.22% | ||
| EDIT - CBIO | 35% Loosely correlated | -11.09% | ||
| STRO - CBIO | 34% Loosely correlated | -17.09% | ||
| VYGR - CBIO | 34% Loosely correlated | -5.29% | ||
More | ||||
UTHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, UTHR has been loosely correlated with MNKD. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if UTHR jumps, then MNKD could also see price increases.
| Ticker / NAME | Correlation To UTHR | 1D Price Change % | ||
|---|---|---|---|---|
| UTHR | 100% | -1.22% | ||
| MNKD - UTHR | 38% Loosely correlated | -2.56% | ||
| GERN - UTHR | 37% Loosely correlated | -1.64% | ||
| ALNY - UTHR | 36% Loosely correlated | -1.41% | ||
| CBIO - UTHR | 36% Loosely correlated | -10.72% | ||
| INSM - UTHR | 35% Loosely correlated | -1.80% | ||
More | ||||